WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 319543
CAS#: 913088-80-9
Description: Cenobamate, also known as YKP-3089, is a novel new antiepileptic drug candidate. Cenobamate showed broad-spectrum anticonvulsant activity. Cenobamate was approved in 11/21/2019 for treatment of partial onset seizures
MedKoo Cat#: 319543
Name: Cenobamate
CAS#: 913088-80-9
Chemical Formula: C10H10ClN5O2
Exact Mass: 267.0523
Molecular Weight: 267.67
Elemental Analysis: C, 44.87; H, 3.77; Cl, 13.24; N, 26.16; O, 11.95
Cenobamate is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.
Related CAS #: 913088-80-9 913087-59-9
Synonym: YKP-3089; YKP3089; YKP3089; Cenobamate; Xcopri
IUPAC/Chemical Name: (R)-1-(2-chlorophenyl)-2-(2H-tetrazol-2-yl)ethyl carbamate
InChi Key: GFHAXPJGXSQLPT-VIFPVBQESA-N
InChi Code: InChI=1S/C10H10ClN5O2/c11-8-4-2-1-3-7(8)9(18-10(12)17)5-16-14-6-13-15-16/h1-4,6,9H,5H2,(H2,12,17)/t9-/m0/s1
SMILES Code: NC(O[C@H](C1=CC=CC=C1Cl)CN2N=CN=N2)=O
The following data is based on the product molecular weight 267.67 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Arnold S. Cenobamate: new hope for treatment-resistant epilepsy. Lancet Neurol. 2019 Nov 13. pii: S1474-4422(19)30434-X. doi: 10.1016/S1474-4422(19)30434-X. [Epub ahead of print] PubMed PMID: 31734104.
2: Krauss GL, Klein P, Brandt C, Lee SK, Milanov I, Milovanovic M, Steinhoff BJ, Kamin M. Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial. Lancet Neurol. 2019 Nov 13. pii: S1474-4422(19)30399-0. doi: 10.1016/S1474-4422(19)30399-0. [Epub ahead of print] PubMed PMID: 31734103.
3: Kasteleijn-Nolst Trenite DGA, DiVentura BD, Pollard JR, Krauss GL, Mizne S, French JA. Suppression of the photoparoxysmal response in photosensitive epilepsy with cenobamate (YKP3089). Neurology. 2019 Aug 6;93(6):e559-e567. doi: 10.1212/WNL.0000000000007894. Epub 2019 Jul 10. PubMed PMID: 31292226; PubMed Central PMCID: PMC6709996.
4: Nakamura M, Cho JH, Shin H, Jang IS. Effects of cenobamate (YKP3089), a newly developed anti-epileptic drug, on voltage-gated sodium channels in rat hippocampal CA3 neurons. Eur J Pharmacol. 2019 Jul 15;855:175-182. doi: 10.1016/j.ejphar.2019.05.007. Epub 2019 May 4. PubMed PMID: 31063770.
5: Zaccara G, Schmidt D. Antiepileptic Drugs in Clinical Development: Differentiate or Die? Curr Pharm Des. 2017;23(37):5593-5605. doi: 10.2174/1381612823666170809100524. Review. PubMed PMID: 28799516.
6: Zaccara G, Schmidt D. Do traditional anti-seizure drugs have a future? A review of potential anti-seizure drugs in clinical development. Pharmacol Res. 2016 Feb;104:38-48. doi: 10.1016/j.phrs.2015.12.011. Epub 2015 Dec 12. Review. PubMed PMID: 26689774.